ShiraniAZhaoYKarimM, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA2012; 308(3): 247–256.
2.
BovisFSignoriACarmiscianoL, et al. Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. Ann Neurol2018; 84(4): 621–625.
3.
KalincikTBrownJWLRobertsonN, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: A cohort study. Lancet Neurol2017; 16(4): 271–281.
4.
HershCMLoveTEBandyopadhyayA, et al. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Mult Scler J Exp Transl Clin2017; 3(3): 2055217317715485.
5.
KalincikTKubala HavrdovaEHorakovaD, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry2019; 90: 458–468.
6.
HoPRKoendgenHCampbellN, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies. Lancet Neurol2017; 16(11): 925–933.
7.
FordINorrieJ.Pragmatic trials. N Eng J Med2016; 375(5): 454–463.
